PBM is working with its medical advisory board and other experts to introduce DHA /TG dominant products with significant clinical benefits for patients and the healthcare providers who treat them.
Charlottesville, VA (PRWEB) October 16, 2012
PBM Pharmaceuticals, Inc. (PBM) announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 8,173,160 to PBM. This is the second patent issued within the past year to PBM for Omega-3 DHA dominant formulations featuring DHA in its Triglyceride (TG) form. The patents, offering protection through July 2028 and July 2026 respectively, are the result of PBM’s early recognition of the value of the TG form of DHA (DHA/TG), which at the time the patents were filed in 2005, was generally considered a relatively undifferentiated component of Omega-3’s.
PBM plans to build on its preliminary small scale clinical trials that showed great promise for its DHA/TG dominant Omega-3 Product for cardiological indications, by commencing full scale clinical trials. PBM also believes that significant opportunities exist in other areas such as ophthalmic health.
Paul B Manning, Chairman and CEO of PBM Pharmaceuticals, Inc. said: “PBM Pharmaceuticals Inc., has long believed in the potential health benefits of the Triglyceride form of DHA and filed these patents at a time (2005) when DHA was generally referred to as one of several components of Omega-3’s and there was little differentiation of the Triglyceride form of Omega-3’s from the synthetic ethyl ester forms. PBM has been gratified by the growing acceptance of DHA as an extremely important form of Omega-3, and with the growing recognition that the triglyceride form of Omega-3 has significant advantages and benefits when compared to the synthesized ethyl ester form. We believe the growing body of knowledge in this area validates our efforts to obtain these patents.”
Kevin W Combs EVP of PBM Pharmaceuticals added “As more studies and information refine the physicians’ and the public’s understanding of the different components and forms of Omega-3’s, physicians and patients are requesting more natural, effective and safe options to address challenging health issues. PBM believes DHA/TG dominant Omega-3 products are part of this trend and PBM is working with its medical advisory board and other experts to introduce DHA /TG dominant products with significant clinical benefits for patients and the healthcare providers who treat them.”
For additional information or to discuss potential licensing opportunities for DHA/TG dominant products outside their current development program please contact: Kevin Combs or Sean Stalfort at 434-980-8100.